IDiyas

For the Inventor, By the Inventor

San Diego, CA, United States of America

Jingjing Zhao

USPTO Granted Patents = 19 

 

Average Co-Inventor Count = 14.6

ph-index = 7

Forward Citations = 179(Granted Patents)


Company Filing History:

goldMedal19 out of 169 
 
Signal Pharmaceuticals, Inc.
 patents

Years Active: 2012-2023

Loading Chart...
Loading Chart...
19 patents (USPTO):
1. 11590139 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2023-02-28),
2. 11292796 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2022-04-05),
3. 10940152 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2021-03-09),
4. 10683298 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2020-06-16),
5. 10646493 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2020-05-12),
6. 10398700 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2019-09-03),
7. 10167290 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2019-01-01),
8. 10149849 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2018-12-11),
9. 9771371 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2017-09-26),
10. 9737541 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2017-08-22),
11. 9512124 - Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith (2016-12-06),
12. 9193692 - Halogen substituted pyrazines as intermediates of mTOR kinase inhibitors (2015-11-24),
13. 9079900 - Methods of synthesis and purification of heteroaryl compounds (2015-07-14),
14. 8907087 - Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors (2014-12-09),
15. 8569494 - Methods of synthesis and purification of heteroaryl compounds (2013-10-29),

Title: The Innovative Contributions of Jingjing Zhao

Introduction: Jingjing Zhao is a prominent inventor based in San Diego, CA, known for his significant contributions to the field of pharmaceutical innovations. With a remarkable portfolio of 19 patents, Zhao has been at the forefront of developing novel compounds and therapeutic methods.

Latest Patents: Zhao's latest inventions include groundbreaking patents such as "Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith," which focuses on Aminopurine Compounds characterized by unique structures. Additionally, he has developed "Substituted pyrazino[2,3-b]pyrazines as mTOR kinase inhibitors," presenting new Heteroaryl Compounds and innovative preparation methods for these compounds.

Career Highlights: As an inventor at Signal Pharmaceuticals, Inc., Zhao has played an essential role in advancing drug development and therapeutic strategies. His innovative work has not only enhanced the company's portfolio but also contributed to significant advancements in medical treatments.

Collaborations: Throughout his career, Zhao has worked alongside esteemed colleagues, including John J. Sapienza and Patrick Papa. These collaborations have fostered a dynamic environment for innovation and have enabled the development of cutting-edge pharmaceutical solutions.

Conclusion: Jingjing Zhao's dedication to innovation and his impressive number of patents underscore his significant impact on the field of pharmaceuticals. His work continues to pave the way for new treatments and therapies, reflecting the essence of progress in medical research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…